The Global C-Reactive Protein Testing market is expected to reach USD 1.75 billion by 2023 from USD 1.62 billion in 2018, growing at a CAGR of 1.5 % from 2018 to 2023. Growing occurrences of Non Communicable Diseases (NCDs) such as Cardiovascular Diseases, Diabetes and other inflammatory diseases are the major drivers for this market. Point of Care technology for CRP testing is also being used for diagnostic purposes.

Note:1 Above Segmentation May Change During the Course of Planned Research Work.2 Financials, Recent Developments Might Not Be Captured in Case of Unlisted Companies.

The Global C-Reactive Protein Testing market is expected to reach USD 1.75 billion by 2023 from USD 1.62 billion in 2018, growing at a CAGR of 1.5 % from 2018 to 2023. Growing occurrences of Non Communicable Diseases (NCDs) such as Cardiovascular Diseases, Diabetes and other inflammatory diseases are the major drivers for this market. Point of Care technology for CRP testing is also being used for diagnostic purposes.

North America dominates the C-Reactive Protein Testing market with the U.S. accounting for a major market share. This market is primarily driven by the increasing incidences of chronic NCDs. The Asian market is poised to grow at the highest CAGR during the forecast period owing to increasing use in clinical settings as well as increasing government funding in healthcare.